Cleveland Clinic has joined the ongoing efforts of 23andMe.

Fox Base, the National Parkinson Base and the Parkinson’s Institute – is to discover how genes and the surroundings impact Parkinson’s disease. ‘We are aware of the limitations of today’s treatments, therefore we are always considering what we can do to progress the care of this incurable disease,’ said Andre Machado, M.D., Ph.D., Director of Cleveland Clinic’s Center for Neurological Restoration. ‘This collaboration can help us to learn more about the genomics of Parkinson’s disease and how it may impact individualized care in the future.’ The project is part of Cleveland Clinic’s personalized healthcare initiative, which aims to drive discoveries that allow doctors to better predict risk for disease and response to therapies, with the best goal to boost patient treatment.Poor glaucoma follow-up can be a widespread problem – – especially among medically underserved groupings – – that leads to unnecessary vision loss. The analysis investigated whether barriers were linked to ethnicity also. Bradford W. Lee, MD, Stanford University School of Medicine, led the joint task by University and Stanford of California, San Francisco, Division of Ophthalmology. Many eyes care professionals assume these patients skip appointments due to financial problems, insurance problems, or insufficient understanding of the necessity for follow-up treatment, stated Dr. Lee, but our results show various other factors are more essential, and that barriers vary somewhat with patient ethnicity. The most vexing issues were very long clinic wait times and appointment scheduling complications, from August 2008 to January 2009 based on the 152 SFGH clinic individuals surveyed.